Research - The sector-tracking iShares NASDAQ biotechnology ETF (IBB) took out some major levels of resistance in the Thursday trading session, catching the attention of traders in the … Continue Reading
Read nowResearch - The regulatory and legislative environment has improved dramatically in the last half-decade for antibiotics developers, with some new incentives still in the works, and we … Continue Reading
Read nowRecap - Sarepta Therapeutics (SRPT) on Thursday morning released its fourth quarter and full-year 2013 financial results. The company continues to await guidance from the FDA on the … Continue Reading
Read nowRecap - Just remember – it’s not a win until you’ve locked in those profits. Buying Retrophin (RTRX) when PropThink suggested going long the stock on the day it up-listed to … Continue Reading
Read nowInsights - Our entire editorial team was in San Francisco this week for the annual confluence of biotech conferences – JP Morgan Healthcare, Biotech Showcase, and OneMedForum … Continue Reading
Read nowResearch - Since we last profiled Cubist Pharmaceuticals (CBST) in August, shares of the antibiotics company have posted a somewhat muted performance, rising less than 8% versus … Continue Reading
Read nowInsights - AcelRx (ACRX) announced on Monday a partnership with Grunenthal GmbH for the commercialization of Zalviso, the company’s patient-controlled analgesia product, in Europe and Australia. On Thursday, AcelRx entered into … Continue Reading
Read now
